Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03471117 · ClinicalTrials.gov registry record · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
A Phase 4 study of Chronic Kidney Diseases, sponsored by The University of Texas at Arlington.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT03471117: Recruiting Phase 4 study of Chronic Kidney Diseases, sponsored by The University of Texas at Arlington.
NCT03471117 is a Phase 4 study of Chronic Kidney Diseases that is actively recruiting participants, run by The University of Texas at Arlington. The registered enrollment target is 28 participants, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03471117, a Phase 4 study of Chronic Kidney Diseases, is actively recruiting participants, sponsored by The University of Texas at Arlington.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function. The goal of this study is to determine whether a short-term treatment with pioglitazone can reduce sympathetic nerve impulses throughout the body in CKD patients.
Primary Outcome
Multiunit postganglionic MSNA will be recorded using standard microneurographic techniques. Briefly, a unipolar tungsten microelectrode will be inserted into the peroneal nerve near the fibular head of the leg. Neural signals will be amplified, filtered (bandwidth, 700-2,000 Hz), rectified, and integrated (time constant, 0.1 s) to obtain mean voltage neurograms.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Pioglitazone
Study Locations (2)
Texas
- University of Texas at Arlington - Arlington
- UT Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 4 |
What NCT03471117 shows while recruiting
NCT03471117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03471117 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03471117 about?
NCT03471117 is a clinical study titled "Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients". Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typ...
What is the current status of trial NCT03471117?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2018-04-01. Estimated completion is 2026-04-01.
What conditions does trial NCT03471117 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases.
What interventions are being tested in trial NCT03471117?
The interventions under investigation include: Placebo (OTHER), Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT03471117?
This trial is sponsored by The University of Texas at Arlington, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03471117 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03471117's enrollment target sits among peer trials
28 67th of 73 higher than 7 of 73 other Chronic Kidney Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oral Iron in Children With Chronic Kidney Disease
RECRUITING · Phase 4
-
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
RECRUITING · Phase 4
-
Ferric Citrate in ESRD Pilot Project
ACTIVE NOT RECRUITING · Phase 4
-
Immunogenicity of HPV Vaccine in Transplant Recipients.
ACTIVE NOT RECRUITING · Phase 4
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
- NCT03842943 · 28 participants · Phase 2
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI